C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition

Tae Min Cho, Ji Young Kim, Yoon Jae Kim, Daeil Sung, Eunhye Oh, Seojin Jang, Lee Farrand, Van Hai Hoang, Cong Truong Nguyen, Jihyae Ann, Jeewoo Lee, Jae Hong Seo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is an aggressive heterogeneous disease with a divergent profile. It has an earlier tendency to form metastases and is associated with poor clinical outcomes due to the limited treatment options available. Heat-shock protein (HSP90) represents a potential treatment target as it promotes tumor progression and metastasis by modulating the maturation and stabilization of signal transduction proteins. We sought to investigate the efficacy of the C-terminal HSP90 inhibitor L80 on cell proliferation, breast cancer stem cell (BCSC)-like properties, tumor growth and metastasis. L80 suppressed cell viability and concomitantly inhibited AKT/MEK/ERK/JAK2/STAT3 signaling in TNBC cells but did not induce cytotoxicity in normal cells. L80 effectively targeted BCSC-like traits, together with significant reductions in the CD44high/CD24low-population, ALDH1 activity and mammosphere forming-ability. In support of the in vitro observations, L80 administration caused significant impairment in tumor growth, angiogenesis and distant metastases in an orthotopic allograft model with BCSC-enriched cells in vivo. These phenomena were associated with the suppression of BCSC-like characteristics and STAT3 dysfunction. Our findings highlight properties of the L80 compound that may be useful in suppressing metastatic TNBC.

Original languageEnglish
Pages (from-to)141-153
Number of pages13
JournalCancer Letters
Volume447
DOIs
Publication statusPublished - 2019 Apr 10

Fingerprint

Triple Negative Breast Neoplasms
Neoplastic Stem Cells
Breast Neoplasms
Neoplasm Metastasis
HSP90 Heat-Shock Proteins
Neoplasms
Mitogen-Activated Protein Kinase Kinases
Growth
Allografts
Signal Transduction
Cell Survival
Cell Proliferation
Population
Proteins

Keywords

  • C-terminal HSP90 inhibitor
  • Cancer stem cells
  • L80
  • Metastasis
  • STAT3
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. / Cho, Tae Min; Kim, Ji Young; Kim, Yoon Jae; Sung, Daeil; Oh, Eunhye; Jang, Seojin; Farrand, Lee; Hoang, Van Hai; Nguyen, Cong Truong; Ann, Jihyae; Lee, Jeewoo; Seo, Jae Hong.

In: Cancer Letters, Vol. 447, 10.04.2019, p. 141-153.

Research output: Contribution to journalArticle

Cho, TM, Kim, JY, Kim, YJ, Sung, D, Oh, E, Jang, S, Farrand, L, Hoang, VH, Nguyen, CT, Ann, J, Lee, J & Seo, JH 2019, 'C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition', Cancer Letters, vol. 447, pp. 141-153. https://doi.org/10.1016/j.canlet.2019.01.029
Cho, Tae Min ; Kim, Ji Young ; Kim, Yoon Jae ; Sung, Daeil ; Oh, Eunhye ; Jang, Seojin ; Farrand, Lee ; Hoang, Van Hai ; Nguyen, Cong Truong ; Ann, Jihyae ; Lee, Jeewoo ; Seo, Jae Hong. / C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. In: Cancer Letters. 2019 ; Vol. 447. pp. 141-153.
@article{cd34a89acfda45aab268231edb0220ac,
title = "C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition",
abstract = "Triple-negative breast cancer (TNBC) is an aggressive heterogeneous disease with a divergent profile. It has an earlier tendency to form metastases and is associated with poor clinical outcomes due to the limited treatment options available. Heat-shock protein (HSP90) represents a potential treatment target as it promotes tumor progression and metastasis by modulating the maturation and stabilization of signal transduction proteins. We sought to investigate the efficacy of the C-terminal HSP90 inhibitor L80 on cell proliferation, breast cancer stem cell (BCSC)-like properties, tumor growth and metastasis. L80 suppressed cell viability and concomitantly inhibited AKT/MEK/ERK/JAK2/STAT3 signaling in TNBC cells but did not induce cytotoxicity in normal cells. L80 effectively targeted BCSC-like traits, together with significant reductions in the CD44high/CD24low-population, ALDH1 activity and mammosphere forming-ability. In support of the in vitro observations, L80 administration caused significant impairment in tumor growth, angiogenesis and distant metastases in an orthotopic allograft model with BCSC-enriched cells in vivo. These phenomena were associated with the suppression of BCSC-like characteristics and STAT3 dysfunction. Our findings highlight properties of the L80 compound that may be useful in suppressing metastatic TNBC.",
keywords = "C-terminal HSP90 inhibitor, Cancer stem cells, L80, Metastasis, STAT3, Triple-negative breast cancer",
author = "Cho, {Tae Min} and Kim, {Ji Young} and Kim, {Yoon Jae} and Daeil Sung and Eunhye Oh and Seojin Jang and Lee Farrand and Hoang, {Van Hai} and Nguyen, {Cong Truong} and Jihyae Ann and Jeewoo Lee and Seo, {Jae Hong}",
year = "2019",
month = "4",
day = "10",
doi = "10.1016/j.canlet.2019.01.029",
language = "English",
volume = "447",
pages = "141--153",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition

AU - Cho, Tae Min

AU - Kim, Ji Young

AU - Kim, Yoon Jae

AU - Sung, Daeil

AU - Oh, Eunhye

AU - Jang, Seojin

AU - Farrand, Lee

AU - Hoang, Van Hai

AU - Nguyen, Cong Truong

AU - Ann, Jihyae

AU - Lee, Jeewoo

AU - Seo, Jae Hong

PY - 2019/4/10

Y1 - 2019/4/10

N2 - Triple-negative breast cancer (TNBC) is an aggressive heterogeneous disease with a divergent profile. It has an earlier tendency to form metastases and is associated with poor clinical outcomes due to the limited treatment options available. Heat-shock protein (HSP90) represents a potential treatment target as it promotes tumor progression and metastasis by modulating the maturation and stabilization of signal transduction proteins. We sought to investigate the efficacy of the C-terminal HSP90 inhibitor L80 on cell proliferation, breast cancer stem cell (BCSC)-like properties, tumor growth and metastasis. L80 suppressed cell viability and concomitantly inhibited AKT/MEK/ERK/JAK2/STAT3 signaling in TNBC cells but did not induce cytotoxicity in normal cells. L80 effectively targeted BCSC-like traits, together with significant reductions in the CD44high/CD24low-population, ALDH1 activity and mammosphere forming-ability. In support of the in vitro observations, L80 administration caused significant impairment in tumor growth, angiogenesis and distant metastases in an orthotopic allograft model with BCSC-enriched cells in vivo. These phenomena were associated with the suppression of BCSC-like characteristics and STAT3 dysfunction. Our findings highlight properties of the L80 compound that may be useful in suppressing metastatic TNBC.

AB - Triple-negative breast cancer (TNBC) is an aggressive heterogeneous disease with a divergent profile. It has an earlier tendency to form metastases and is associated with poor clinical outcomes due to the limited treatment options available. Heat-shock protein (HSP90) represents a potential treatment target as it promotes tumor progression and metastasis by modulating the maturation and stabilization of signal transduction proteins. We sought to investigate the efficacy of the C-terminal HSP90 inhibitor L80 on cell proliferation, breast cancer stem cell (BCSC)-like properties, tumor growth and metastasis. L80 suppressed cell viability and concomitantly inhibited AKT/MEK/ERK/JAK2/STAT3 signaling in TNBC cells but did not induce cytotoxicity in normal cells. L80 effectively targeted BCSC-like traits, together with significant reductions in the CD44high/CD24low-population, ALDH1 activity and mammosphere forming-ability. In support of the in vitro observations, L80 administration caused significant impairment in tumor growth, angiogenesis and distant metastases in an orthotopic allograft model with BCSC-enriched cells in vivo. These phenomena were associated with the suppression of BCSC-like characteristics and STAT3 dysfunction. Our findings highlight properties of the L80 compound that may be useful in suppressing metastatic TNBC.

KW - C-terminal HSP90 inhibitor

KW - Cancer stem cells

KW - L80

KW - Metastasis

KW - STAT3

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85060939225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060939225&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2019.01.029

DO - 10.1016/j.canlet.2019.01.029

M3 - Article

C2 - 30703411

AN - SCOPUS:85060939225

VL - 447

SP - 141

EP - 153

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -